HC Wainwright & Co. Reiterates Buy Rating on Akebia Therapeutics, Inc. (AKBA)

Market Context

Akebia Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $1.21 with a market capitalization of $347.6M. The stock has declined 68.8% over the past 52 weeks.

Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Akebia Therapeutics, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Akebia Therapeutics, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 01, 2026	HC Wainwright & Co.	Buy	N/A
Apr 07, 2026	BTIG	Buy	N/A
Feb 25, 2026	BTIG	Buy	N/A
Feb 06, 2026	Piper Sandler	Overweight	N/A
Feb 06, 2026	HC Wainwright & Co.	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View AKBA Stock Page